title: Mitigation of NADH: ubiquinone oxidoreductase deficiency by chronic Trolox treatment.
abstract: Deficiency of mitochondrial NADH:ubiquinone oxidoreductase (complex I), is associated with a variety of clinical phenotypes such as Leigh syndrome, encephalomyopathy and cardiomyopathy. Circumstantial evidence suggests that increased reactive oxygen species (ROS) levels contribute to the pathogenesis of these disorders. Here we assessed the effect of the water-soluble vitamin E derivative Trolox on ROS levels, and the amount and activity of complex I in fibroblasts of six children with isolated complex I deficiency caused by a mutation in the NDUFS1, NDUFS2, NDUFS7, NDUFS8 or NDUFV1 gene. Patient cells displayed increased ROS levels and a variable decrease in complex I activity and amount. For control cells, the ratio between activity and amount was 1 whereas for the patients this ratio was below 1, indicating a defect in intrinsic catalytic activity of complex I in the latter cells. Trolox treatment dramatically reduced ROS levels in both control and patient cells, which was paralleled by a substantial increase in the amount of complex I. Although the ratio between the increase in activity and amount of complex I was exactly proportional in control cells it varied between 0.1 and 0.8 for the patients. Our findings suggest that the expression of complex I is regulated by ROS. Furthermore, they provide evidence that both the amount and intrinsic activity of complex I are decreased in inherited complex I deficiency. The finding that Trolox treatment increased the amount of complex I might aid the future development of antioxidant treatment strategies for patients. However, such treatment may only be beneficial to patients with a relatively small reduction in intrinsic catalytic defect of the complex.
authors.affiliation: Department of Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, The Netherlands. w.koopman@ncmls.ru.nl
authors.forename: Werner J H
authors.initials: WJ
authors.lastname: Koopman
authors.forename: Sjoerd
authors.initials: S
authors.lastname: Verkaart
authors.forename: Sjenet E
authors.initials: SE
authors.lastname: van Emst-de Vries
authors.forename: Sander
authors.initials: S
authors.lastname: Grefte
authors.forename: Jan A M
authors.initials: JA
authors.lastname: Smeitink
authors.forename: Leo G J
authors.initials: LG
authors.lastname: Nijtmans
authors.forename: Peter H G M
authors.initials: PH
authors.lastname: Willems
mesh_terms: D002839:Chromans / Q000494:pharmacology*; D042967:Electron Transport Complex I / Q000172:deficiency* / Q000187:drug effects / Q000235:genetics*; D005347:Fibroblasts / Q000201:enzymology; D030342:Genetic Diseases, Inborn / Q000201:enzymology / Q000235:genetics; D006801:Humans; D007700:Kinetics; D008928:Mitochondria / Q000201:enzymology; D009154:Mutation; D010085:Oxidative Phosphorylation; D010641:Phenotype; D021122:Protein Subunits / Q000235:genetics; D012867:Skin / Q000201:enzymology
chemical_list: D002839:Chromans; D021122:Protein Subunits; D042967:Electron Transport Complex I; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid